Science & Technology
Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44DA063266-01
Award Ceiling
$1.5M
Award Floor
$1.5M
Close Date
Mar 31, 2027
381 days leftTotal Funding
$1.5M
Expected Awards
1
Posted Date
Apr 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44DA063266-01
Description
SBIR Phase Phase II award: "Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2" awarded to MYOSIN THERAPEUTICS INC in JUPITER, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,496,586. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.